midazolam d4 Search Results


midazolam-d4  (Lipomed)
90
Lipomed midazolam-d4
Midazolam D4, supplied by Lipomed, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midazolam+d4/midazolam+d4/pm31892043-49-9-19
Average 90 stars, based on 1 article reviews
midazolam-d4 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
antipyrine, midazolam and ketoconazole and sulfasalazine-d4  (FUJIFILM)
90
FUJIFILM antipyrine, midazolam and ketoconazole and sulfasalazine-d4
Antipyrine, Midazolam And Ketoconazole And Sulfasalazine D4, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midazolam+d4/antipyrine++midazolam+and+ketoconazole+and+sulfasalazine+d4/pm39622870-142-5-9
Average 90 stars, based on 1 article reviews
antipyrine, midazolam and ketoconazole and sulfasalazine-d4 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
midazolam d4 maleate  (Cerilliant Corporation)
86
Cerilliant Corporation midazolam d4 maleate
SPA70 reduces the metabolism and enhances the efficacy of chemotherapeutic agents. a , b SPA70 reduces the metabolism of paclitaxel (PTX) in primary human hepatocytes (PHHs). In a , PHHs were pretreated for 72 h with 0.1% DMSO, 1.6 µM RIF or 0.5 µM or 5 µM PTX in the presence or absence of 10 µM SPA70 before receiving 3.3 µM <t>midazolam</t> (MDZ) and being incubated for a further 4 h. The concentrations of 1′-OH MDZ (an MDZ metabolite) in the medium for each treatment were determined using LC/MS/MS. In b , PHHs were treated with 1 µM PTX in the presence or absence of 10 µM SPA70. The concentrations of PTX metabolites, 3-p-OH PTX (generated by CYP3A4) and 6α-OH PTX (generated by CYP2C8), were determined using LC/MS/MS. Each data point represents the compound concentration measured after 24 or 48 h of treatment. Data are expressed as the mean and 95% confidence interval (CI). c , d hPXR levels inversely correlate with the sensitivity of cancer cells to PTX. In c , LS180 cells with (hPXR overexpression) or without (parental cells) stable exogenous expression of hPXR were treated with PTX in the presence or absence of 10 µM SPA70 for 96 h before a CellTiter-Glo assay was performed. The vehicle was DMSO. In d , SNU-C4 cells treated with pooled siRNAs (siPXR_pool) or individual siRNAs (siPXR_1, 2, 3 and 4) targeting hPXR, or with nontargeting controls (siNT) with or without SPA70, were treated with PTX for 96 h before a CellTiter-Glo assay was performed. The ‘% normalized growth’ was determined by normalizing the luminescent signal from compound-treated cells to that from DMSO-treated cells. The drug concentration is expressed using a log scale. Final DMSO concentration was 0.2% in a – d . The half-maximal inhibitory concentration (IC 50 ) is indicated. Data are presented as the means ± S.E.M. ( n = 4 in c and n = 3 in d ). * P < 0.05, ** P < 0.01 or **** P < 0.0001 for each group relative to the parental cells/vehicle in c or siNT-treated cells in d . Statistical significance was calculated by one-way analysis of variance with Tukey’s multiple-comparison test
Midazolam D4 Maleate, supplied by Cerilliant Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midazolam+d4/Midazolam-D4+maleate+(0%2E1+mg%2Fml)+(as+free+base)+in+Methanol/pmc05622171-269-0-5
Average 86 stars, based on 1 article reviews
midazolam d4 maleate - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
istd midazolam-d4  (Alsachim SAS)
90
Alsachim SAS istd midazolam-d4
SPA70 reduces the metabolism and enhances the efficacy of chemotherapeutic agents. a , b SPA70 reduces the metabolism of paclitaxel (PTX) in primary human hepatocytes (PHHs). In a , PHHs were pretreated for 72 h with 0.1% DMSO, 1.6 µM RIF or 0.5 µM or 5 µM PTX in the presence or absence of 10 µM SPA70 before receiving 3.3 µM <t>midazolam</t> (MDZ) and being incubated for a further 4 h. The concentrations of 1′-OH MDZ (an MDZ metabolite) in the medium for each treatment were determined using LC/MS/MS. In b , PHHs were treated with 1 µM PTX in the presence or absence of 10 µM SPA70. The concentrations of PTX metabolites, 3-p-OH PTX (generated by CYP3A4) and 6α-OH PTX (generated by CYP2C8), were determined using LC/MS/MS. Each data point represents the compound concentration measured after 24 or 48 h of treatment. Data are expressed as the mean and 95% confidence interval (CI). c , d hPXR levels inversely correlate with the sensitivity of cancer cells to PTX. In c , LS180 cells with (hPXR overexpression) or without (parental cells) stable exogenous expression of hPXR were treated with PTX in the presence or absence of 10 µM SPA70 for 96 h before a CellTiter-Glo assay was performed. The vehicle was DMSO. In d , SNU-C4 cells treated with pooled siRNAs (siPXR_pool) or individual siRNAs (siPXR_1, 2, 3 and 4) targeting hPXR, or with nontargeting controls (siNT) with or without SPA70, were treated with PTX for 96 h before a CellTiter-Glo assay was performed. The ‘% normalized growth’ was determined by normalizing the luminescent signal from compound-treated cells to that from DMSO-treated cells. The drug concentration is expressed using a log scale. Final DMSO concentration was 0.2% in a – d . The half-maximal inhibitory concentration (IC 50 ) is indicated. Data are presented as the means ± S.E.M. ( n = 4 in c and n = 3 in d ). * P < 0.05, ** P < 0.01 or **** P < 0.0001 for each group relative to the parental cells/vehicle in c or siNT-treated cells in d . Statistical significance was calculated by one-way analysis of variance with Tukey’s multiple-comparison test
Istd Midazolam D4, supplied by Alsachim SAS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midazolam+d4/istd+midazolam+d4/pm25464106-58-0-10
Average 90 stars, based on 1 article reviews
istd midazolam-d4 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
midazolam-d4 maleate - in methanol  (Biosynth Carbosynth)
N/A
   Buy from Supplier
midazolam d4 maleate in methanol  (LGC LoGiCal)
N/A
Midazolam D4 Maleate 0 1 mg ml in Methanol as free base
   Buy from Supplier
midazolam d4  (Cayman Chemical)
N/A
Midazolam d maleate CRM Item No 20199 is intended for use as an internal standard for the quantification of midazolam Item Nos 19391 | 16193 by GC or LC MS Midazolam is used for sedation
   Buy from Supplier
midazolam-d4  (Cayman Chemical)
N/A
   Buy from Supplier

Image Search Results


SPA70 reduces the metabolism and enhances the efficacy of chemotherapeutic agents. a , b SPA70 reduces the metabolism of paclitaxel (PTX) in primary human hepatocytes (PHHs). In a , PHHs were pretreated for 72 h with 0.1% DMSO, 1.6 µM RIF or 0.5 µM or 5 µM PTX in the presence or absence of 10 µM SPA70 before receiving 3.3 µM midazolam (MDZ) and being incubated for a further 4 h. The concentrations of 1′-OH MDZ (an MDZ metabolite) in the medium for each treatment were determined using LC/MS/MS. In b , PHHs were treated with 1 µM PTX in the presence or absence of 10 µM SPA70. The concentrations of PTX metabolites, 3-p-OH PTX (generated by CYP3A4) and 6α-OH PTX (generated by CYP2C8), were determined using LC/MS/MS. Each data point represents the compound concentration measured after 24 or 48 h of treatment. Data are expressed as the mean and 95% confidence interval (CI). c , d hPXR levels inversely correlate with the sensitivity of cancer cells to PTX. In c , LS180 cells with (hPXR overexpression) or without (parental cells) stable exogenous expression of hPXR were treated with PTX in the presence or absence of 10 µM SPA70 for 96 h before a CellTiter-Glo assay was performed. The vehicle was DMSO. In d , SNU-C4 cells treated with pooled siRNAs (siPXR_pool) or individual siRNAs (siPXR_1, 2, 3 and 4) targeting hPXR, or with nontargeting controls (siNT) with or without SPA70, were treated with PTX for 96 h before a CellTiter-Glo assay was performed. The ‘% normalized growth’ was determined by normalizing the luminescent signal from compound-treated cells to that from DMSO-treated cells. The drug concentration is expressed using a log scale. Final DMSO concentration was 0.2% in a – d . The half-maximal inhibitory concentration (IC 50 ) is indicated. Data are presented as the means ± S.E.M. ( n = 4 in c and n = 3 in d ). * P < 0.05, ** P < 0.01 or **** P < 0.0001 for each group relative to the parental cells/vehicle in c or siNT-treated cells in d . Statistical significance was calculated by one-way analysis of variance with Tukey’s multiple-comparison test

Journal: Nature Communications

Article Title: SPA70 is a potent antagonist of human pregnane X receptor

doi: 10.1038/s41467-017-00780-5

Figure Lengend Snippet: SPA70 reduces the metabolism and enhances the efficacy of chemotherapeutic agents. a , b SPA70 reduces the metabolism of paclitaxel (PTX) in primary human hepatocytes (PHHs). In a , PHHs were pretreated for 72 h with 0.1% DMSO, 1.6 µM RIF or 0.5 µM or 5 µM PTX in the presence or absence of 10 µM SPA70 before receiving 3.3 µM midazolam (MDZ) and being incubated for a further 4 h. The concentrations of 1′-OH MDZ (an MDZ metabolite) in the medium for each treatment were determined using LC/MS/MS. In b , PHHs were treated with 1 µM PTX in the presence or absence of 10 µM SPA70. The concentrations of PTX metabolites, 3-p-OH PTX (generated by CYP3A4) and 6α-OH PTX (generated by CYP2C8), were determined using LC/MS/MS. Each data point represents the compound concentration measured after 24 or 48 h of treatment. Data are expressed as the mean and 95% confidence interval (CI). c , d hPXR levels inversely correlate with the sensitivity of cancer cells to PTX. In c , LS180 cells with (hPXR overexpression) or without (parental cells) stable exogenous expression of hPXR were treated with PTX in the presence or absence of 10 µM SPA70 for 96 h before a CellTiter-Glo assay was performed. The vehicle was DMSO. In d , SNU-C4 cells treated with pooled siRNAs (siPXR_pool) or individual siRNAs (siPXR_1, 2, 3 and 4) targeting hPXR, or with nontargeting controls (siNT) with or without SPA70, were treated with PTX for 96 h before a CellTiter-Glo assay was performed. The ‘% normalized growth’ was determined by normalizing the luminescent signal from compound-treated cells to that from DMSO-treated cells. The drug concentration is expressed using a log scale. Final DMSO concentration was 0.2% in a – d . The half-maximal inhibitory concentration (IC 50 ) is indicated. Data are presented as the means ± S.E.M. ( n = 4 in c and n = 3 in d ). * P < 0.05, ** P < 0.01 or **** P < 0.0001 for each group relative to the parental cells/vehicle in c or siNT-treated cells in d . Statistical significance was calculated by one-way analysis of variance with Tukey’s multiple-comparison test

Article Snippet: Midazolam-D4 maleate was obtained from Cerilliant (Round Rock, TX).

Techniques: Incubation, Liquid Chromatography with Mass Spectroscopy, Generated, Concentration Assay, Over Expression, Expressing, Glo Assay